Fresenius Medical Care, the world’s largest provider of dialysis products and services, today successfully placed bonds in three tranches with an aggregate volume of €1.75 billion.
Continued strong organic revenue growth across all regions; Record growth in home dialysis in North America; Improved earnings growth despite negative ESCO effect; Cost optimization initiatives on track; Outlook 2019 confirmed
Spectra Laboratories broke ground on a 200,000-square-foot laboratory in Southaven, Mississippi yesterday. The project is expected to create more than 300 jobs over the next three years.
Underlying business development in line with expectations; Continued strong organic revenue growth; Healthy growth in the U.S. dialysis business
Fresenius Medical Care is pleased the U.S. Administration’s plans for changing the way care is provided to people with kidney disease supports its existing strategy.